Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma

Completed · Not applicable · Has a placebo group

Conditions studied: Atopic Asthma

In brief

Curcumin has antioxidant properties and in animal models has numerous molecular targets, many of which are intracellular, such as transcription factors AP-1 and NF. As such, it inhibits the secretion of both pro-inflammatory (TNF-, IL-6) and anti-inflammatory (IL-10) cytokines, possibly by inhibiting transcription factors such as nuclear factor-B (NF-B) and activator protein-1 (AP-1) (Wong et al).

Key facts

Study ID

NCT01179256

Run by

University of South Florida

People needed

16

Starts

2009-03-01

Expected to finish

2010-03-01

Last updated by the study team

2010-08-11

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and non-breastfeeding, non-pregnant females
• Aged 18-60 years
• History of physician-diagnosed asthma for 1 year or longer FEV1 60% pre-bronchodilator
• Currently on low or medium dose inhaled corticosteroids (see Appendix 1)
• Use of short-acting β-agonist ≥ 1 in the past 30 days (except for exercise) A ≥ 2+ skin-prick test prick-puncture test to Dermatophagoides pteronyssinus or Dermatophagoidesfarinae with appropriate positive/negative controls (historical is acceptable within 10 years)

Where it is running

• Usf Asthma Allergy and Immunology Cru — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.